IGF-I Regulates Osteoprotegerin ( OPG ) and Receptor Activator of Nuclear Factor-B Ligand in Vitro and OPG in Vivo
暂无分享,去创建一个
R. Marcus | C. Ackert-Bicknell | J. Rubin | T. Murphy | C. Rosen | M. Nanes | W. Beamer | X. Fan | L. Holloway | Li-ping Zhu | R. Marcus | L. Zhu | X. Fan | J. Rubin | W. G. Beamer | C. Rosen | L. Zhu | X. Fan | T. C. Murphy | R. Marcus | L. Holloway
[1] S. Mohan,et al. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. , 2001, Endocrinology.
[2] R. L. Cain,et al. Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. , 2001, Endocrinology.
[3] B. Riggs,et al. Leptin reduces ovariectomy-induced bone loss in rats. , 2001, Endocrinology.
[4] J. Yesavage,et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.
[5] R. Lindsay,et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. , 2000, The Journal of clinical endocrinology and metabolism.
[6] L. Donahue,et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. , 2000, Endocrinology.
[7] J. Rubin,et al. Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells. , 2000, American journal of physiology. Cell physiology.
[8] Kangsheng Wang,et al. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. , 2000, Analytical biochemistry.
[9] D. Lacey,et al. Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. , 1999, Endocrinology.
[10] C. Rosen,et al. Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. , 1999, Clinical chemistry.
[11] S. K. Lee,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with , 2022 .
[12] P. Hindmarsh,et al. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion. , 1999, The Journal of clinical endocrinology and metabolism.
[13] R. Kitazawa,et al. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. , 1999, Biochimica et biophysica acta.
[14] T. Rosén. Effects of GH on Body Composition , 1999 .
[15] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] G. Daculsi,et al. Growth hormone stimulatory effects on osteoclastic resorption are partly mediated by insulin-like growth factor I: an in vitro study. , 1998, Bone.
[17] K. Chihara,et al. Insulin‐like growth factor‐I mediates osteoclast‐like cell formation stimulated by parathyroid hormone , 1997, Journal of cellular physiology.
[18] M. Thorén,et al. Different Responses of Bone Alkaline Phosphatase Isoforms During Recombinant Insulin‐like Growth Factor‐I (IGF‐I) and During Growth Hormone Therapy in Adults with Growth Hormone Deficiency , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] K. Chihara,et al. The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts. , 1997, Hormone research.
[20] L. Sjöström,et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. , 1996, The Journal of clinical endocrinology and metabolism.
[21] L. Mosekilde,et al. Short‐term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: A dose response study , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] R. Marcus,et al. Effects of recombinant insulin‐like growth factor‐I and growth hormone on bone turnover in elderly women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] V. Han,et al. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. , 1995, Bone.
[24] J. Beresford,et al. Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type 1 IGF receptor. , 1995, Bone.
[25] M. Kumegawa,et al. Insulin-like growth factor-I supports formation and activation of osteoclasts. , 1992, Endocrinology.
[26] S. Mohan,et al. Bone growth factors. , 1991, Clinical orthopaedics and related research.
[27] S. Duursma,et al. The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse osteoblasts: autocrine/paracrine growth effect of IGFs? , 1990, The Journal of endocrinology.
[28] E. Canalis,et al. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.
[29] E. Froesch,et al. Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. , 1986, Hormone research.